<DOC>
	<DOC>NCT00162942</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of the Adacolumn Apheresis System as a treatment for the signs and symptoms of Crohn's disease.</brief_summary>
	<brief_title>Study for the Treatment of Crohn's Disease With Adacolumn</brief_title>
	<detailed_description>Trial Features: - Medical device (Non-drug option) - Most patients can remain on current treatment regimen throughout the study Components of the Study: - Study length is 24 weeks, which includes a screening visit, ten treatment visits over nine weeks and 4 follow-up appointments - Physical exams, laboratory tests and disease assessments conducted at no charge to the patient - 2:1 Randomization (treatment:sham) - Open-Label extension offered to eligible patients</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Moderate to severe Crohn's disease Adequate peripheral venous access Agree to participate in the required followup visits Able to complete a diary Signed written informed consent document and authorization for use of protected health information Key Extremely severe Crohn's disease Known obstructive symptoms within the past 3 months Presence of toxic megacolon Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks Total colectomy, ileostomy, stoma or 100 cm of resected small bowel Requiring inpatient hospitalization A history of allergic reaction to heparin or heparininduced thrombocytopenia A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures A history of severe cardiovascular or peripheral arterial diseases A history of cerebral vascular diseases Liver diseases Renal insufficiency Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment Any hypercoagulable disorder Known infection with Hepatitis B or C, or HIV Severe anemia Leukopenia or granulocytopenia Evidence of current systemic infection Malignancy Pregnant, lactating or planning to become pregnant during the course of the investigational study Used within the last 30 days, an investigational drug, biologic or device or 5 halflives, if known, for any investigational drug or biologic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>